Roivant Sciences (ROIV) Tax Provisions (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Tax Provisions came in at $35.0 million in Q4 2025, up 236.8% YoY from $10.4 million in Q4 2024, and up 400.01% on a QoQ basis from $7.0 million in Q3 2025.
Analysis
Roivant Sciences (ROIV) Tax Provisions (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Tax Provisions data on file, last reported at $35.0 million in Q4 2025.
- Quarterly Tax Provisions rose 236.8% year-over-year to $35.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.1 million (down 19.43% YoY) and the FY2026 annual result came in at $133.3 million, up 176.77% from the prior year.
- Tax Provisions climbed to $35.0 million in Q4 2025, from $7.0 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $35.0 million in Q4 2025 to a low of -$25.6 million in Q4 2024.
- A 5-year average of $6.3 million and a median of $4.0 million in 2022 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2022 — Tax Provisions surged 4200.0% — and 2024, when it slumped 193.74%.
- Tracing ROIV's Tax Provisions over 5 years: stood at $532000.0 in 2021, then soared by 1588.53% to $9.0 million in 2022, then jumped by 203.64% to $27.3 million in 2023, then tumbled by 193.74% to -$25.6 million in 2024, then soared by 236.8% to $35.0 million in 2025.
- The last three Tax Provisions figures came in at $35.0 million (Q4 2025), $7.0 million (Q3 2025), and $4.6 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Roivant Sciences | 25.22 Bn | 25.22 Bn | 1.16 Mn | -3.96 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.96 Mn |
| Dec 31, 2025 | 34.98 Mn |
| Sep 30, 2025 | 7.00 Mn |
| Jun 30, 2025 | 4.65 Mn |
| Dec 31, 2024 | -25.57 Mn |
| Sep 30, 2024 | 12.46 Mn |
| Jun 30, 2024 | 11.96 Mn |
| Dec 31, 2023 | 27.28 Mn |
| Sep 30, 2023 | 3.24 Mn |
| Jun 30, 2023 | 1.75 Mn |
| Dec 31, 2022 | 8.98 Mn |
| Sep 30, 2022 | 2.17 Mn |
| Jun 30, 2022 | 4.00 Mn |
| Dec 31, 2021 | 532,000.00 |
| Sep 30, 2021 | 401,000.00 |
| Jun 30, 2021 | 93,000.00 |
| Dec 31, 2020 | -224,000.00 |
| Sep 30, 2020 | 711,000.00 |
| Jun 30, 2020 | 1.22 Mn |